Sideris Pharmaceuticals Inc - MA Middlesex, Lexington 02421

Sideris Pharmaceuticals Inc entered the industry of Commercial Biotechnical Research in 2012 and has grown to employ 1 to 4 people, generating an annual revenue of $100.000 to $499.999. The NAICS classifies this business under the code 541711, which describes it as a Commercial Biotechnical Research. For further clarification, the SIC classifies this business under the code 8731 and described it as a Commercial Biotechnical Research. The business provides service to the B2B market.

To acquire more information, please contact Thomas Neenan by calling (339) 970-8070 during business hours. You can also write to the business’ Single Location at 70 Reed St, Lexington, Massachusetts MA 02421. You can also visit the company’s website at . View this business’ social media profiles on Twitter or on Facebbok .

Company: Sideris Pharmaceuticals Inc
Representative: Thomas Neenan
Place of Business: 70 Reed St, Lexington, MA 02421
Contact Number: (339) 970-8070
Type of Service: Commercial Biotechnical Research
SIC Number: 8731
NAICS Number: 541711
Locality: Single Location
Market Type: B2B (Business to Business)
Began: 2012
Income/Year: $100.000 to $499.999
Laborers: 1 to 4
Share This Company:

Sideris Pharmaceuticals Inc is a company operating from Middlesex, Massachusetts providing professional Commercial Biotechnical Research and relevant B2B variables. It was founded in 2012 and registered with the SIC code 8731 as Commercial Biotechnical Research, and with the NAICS code 541711 as Commercial Biotechnical Research.

With a current employee count of 1 to 4, Sideris Pharmaceuticals Inc has gone to report making $100.000 to $499.999 per annum on its journey towards growth. This company invites you to contact its representative Thomas Neenan at (339) 970-8070 for related queries, or to locate its Single Location using the coordinates .

The Single Location can also be found at the street address 70 Reed St in Lexington, Massachusetts 02421 and can be engaged online through the company website at , the company Twitter , and Facebook page .